预约演示
更新于：2025-02-07
Amlodipine Besylate/Olmesartan Medoxomil
奥美沙坦酯氨氯地平
更新于：2025-02-07
概要
基本信息
药物类型 小分子化药 |
别名 Azor、Ol-Vamlo、Olmersartan medoxomil/amlodipine besilate + [6] |
作用机制 AT1R拮抗剂(血管紧张素II-1型受体拮抗剂)、VDCCs阻滞剂(电压门控性钙通道复合体阻滞剂) |
治疗领域 |
非在研适应症- |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2007-09-26), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C29H30N6O6 |
InChIKeyUQGKUQLKSCSZGY-UHFFFAOYSA-N |
CAS号144689-63-4 |
查看全部结构式(2)
关联
44
项与 奥美沙坦酯氨氯地平 相关的临床试验CTR20244099
山西同达药业有限公司研制的奥美沙坦酯氨氯地平片（规格：20 mg/5 mg）与持证商为第一三共制药（上海）有限公司的奥美沙坦酯氨氯地平片（商品名：Sevikar®，20 mg/5 mg）在中国健康受试者中进行的随机、开放、单剂量、两周期、双交叉、空腹及餐后状态下的生物等效性研究
CTR20242837
奥美沙坦酯左氨氯地平片(20mg/2.5mg)用于奥美沙坦酯片(20mg)或苯磺酸氨氯地平片(5mg)单药治疗4周血压不能有效控制的原发性轻、中度高血压患者的有效性和安全性的随机、双盲双模拟、多中心Ⅲ期临床研究
CTR20242179
健康成年受试者空腹和餐后单次口服奥美沙坦酯氨氯地平片的随机、开放、单剂量、两序列、两制剂、两周期、双交叉设计的生物等效性试验
100 项与 奥美沙坦酯氨氯地平 相关的临床结果
登录后查看更多信息
100 项与 奥美沙坦酯氨氯地平 相关的转化医学
登录后查看更多信息
100 项与 奥美沙坦酯氨氯地平 相关的专利（医药）
登录后查看更多信息
26
项与 奥美沙坦酯氨氯地平 相关的文献（医药）2023-12-12ACS nano
Azo Reductase Activated Magnetic Resonance Tuning Probe with “Switch-On” Property for Specific and Sensitive Tumor Imaging in Vivo
Article
作者: Song, Yang ; Tan, Weihong ; Zhu, Xiaokang ; Li, Linyao ; Li, Yu ; Song, Erqun ; Deng, Siyu ; Gu, Peilin
Cancer remains a threat to human health. However, if tumors can be detected in the early stage, then the effectiveness of cancer treatment could be significantly improved. Therefore, it is worthwhile to develop more sensitive and accurate cancer diagnostic methods. Herein, we demonstrated an azo reductase (AzoR)-activated magnetic resonance tuning (MRET) probe with a "switch-on" property for specific and sensitive tumor imaging in vivo. Specifically, Gd-labeled DNA1 (DNA1-Gd) and cyclodextrin-coated magnetic nanoparticles (MNP-CD) were employed as enhancer and quencher of MRET, respectively, while DNA2, an azobenzene (Azo) group-modified aptamer (AS1411), served as a linker between enhancer and quencher to construct the MRET probe of MNP@DNA(1-2)-Gd. In tumor tissues with high-level AzoR, the T1-weighted magnetic resonance signal of the MRET probe could be restored by intelligently regulating the switch from "OFF" to "ON" after activation with AzoR, thus accurately indicating the location of the tumor accurately. Moreover, the tumor with a 4 times smaller size than that of the normal tumor model could be imaged based on the proposed MRET probe. The as-proposed MRET-based magnetic resonance imaging strategy not only achieves tumor imaging accurately but also shows promise for early diagnosis of tumors, which might improve patients' survival rates and provide an opportunity for image-guided biomedical applications in the future.
2023-12-01Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
The enhancement effect of small molecule Lyb24 reveals AzoR as a novel target of polymyxin B
Article
作者: Huang, Wei ; Hu, Chunxia ; Wang, Xiao ; Zhou, Guibao ; Cheng, Shumin ; Liu, Shiyi ; Zou, Quanming ; Sun, Longqin ; Zhang, Jinyong ; Cui, Ruiqin ; Li, Jingli ; Liu, Jianhua ; Zhao, Yan ; Huang, Ying ; Zeng, Huan
Given the important role of polymyxin B (PB) in the treatment of drug-resistant Gram-negative bacterial infections, the emergence of PB resistance poses a serious threat to public health. Adjuvant development is a supplementary strategy that can compensate for the lack of novel antibiotics by protecting PB. In this study, we found a small molecule named Lyb24 that showed weak antibacterial activity (minimum inhibitory concentration ≥ 10 μg/ml) but potentiated and revitalized the efficacy of PB against Gram-negative pathogens, including mcr-1- and mgrB-deletion-mediated PB-resistant strains. Our results showed that Lyb24 inhibits the translational levels of genes associated with the modification of lipid A. In addition, Lyb24 increases the permeability, disrupts the integrity and induces the depolarization of the membrane. We further found that both Lyb24 and PB could directly bind to AzoR and inhibit its activity. Structural analysis showed that Lyb24 binds to the isoalloxazine ring of flavin mononucleotide (FMN) through pi-pi stacking and loop η4 of AzoR. A pneumonia model was used to confirm that the activity against clinical PB-resistant Klebsiella pneumoniae was enhanced due to Lyb24 on PB. In conclusion, we provide a potential therapeutic regimen by combining Lyb24 and PB to treat Gram-negative-resistant bacterial infections. Our findings not only explain the synergistic effect of Lyb24, but also expand our knowledge on the mechanism of action of PB.
2022-07-01Biophysical chemistry
Sulphonated azo dye decolorization by Alcaligenes faecalis subsp. phenolicus MB207: Insights from laboratory and computational analysis
Article
作者: Yasmin, Azra ; Basharat, Zarrin
Microbial decolorization of azo dyes, mediated by an enzymatic mechanism is an intricate cost-effective, and eco-friendly treatment method of genotoxic azo pollutants. Scientists are on the constant lookout for microbes, enzymes, and mechanisms that could aid remediation of the environment at a fast pace. Alcaligenes faecalis subsp. phenolicus MB207 is one such bacteria, consisting of azoreductase (AzoR) and laccase/multicopper oxidase enzyme responsible for sulphonated mono-azo dye (Methyl orange) and di-azo dye (Congo red) degradation. AzoR degrades dyes by a ping-pong setup while multicopper oxidase achieves this through a non-specified radical approach. We have coupled experimental analysis with bioinformatics for deciphering intricacies of this procedure in tiny scale enzymatic machines of this biotope. The degradation assays were followed by molecular docking of the enzyme-substrate complexes. Key anchoring bonds were detected and mapped H-bonding, electron exchange, ionic interactions, as well as hydrophobic interactions, provided insights into dye-enzyme and NADH-enzyme binding. This study establishes a foundation of the molecular basis of dye interaction with azoR and multicopper oxidase in A. facealis subsp. phenolicus MB207.
100 项与 奥美沙坦酯氨氯地平 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 原发性高血压 | 中国 | 2018-07-12 | |
| 高血压 | 美国 | 2007-09-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 600 | Olmesartan/Amlodipine 40/10 mg | 製範鹹衊艱淵選膚鑰膚(製壓壓壓窪憲網製窪鏇) = 選選膚遞鏇積襯積選鏇 膚鏇觸襯獵遞艱壓憲醖 (鬱積襯糧觸壓鏇襯簾醖 ) 更多 | 积极 | 2013-12-01 | ||
Perindopril/Amlodipine 8/10 mg | 製範鹹衊艱淵選膚鑰膚(製壓壓壓窪憲網製窪鏇) = 廠製廠鑰構淵鹽鬱鹹構 膚鏇觸襯獵遞艱壓憲醖 (鬱積襯糧觸壓鏇襯簾醖 ) 更多 | ||||||
N/A | 292 | 遞廠淵壓膚繭選鹽鹹積(餘艱襯壓衊範窪淵製鏇) = Incidence of study drug related adverse events was comparable in monotherapy and combination therapy group (2.77% vs 2.17%) 鹹網艱齋艱繭積構觸廠 (憲簾構膚製網鏇艱衊遞 ) | 积极 | 2012-09-01 | |||
临床3期 | 2,204 | Olmesartan(OLM) (Olmesartan(OLM) 40 Mg-Amlodipine(AML) 10 mg) | 糧憲顧醖蓋艱鬱鏇壓艱(膚顧觸構鏇壓壓壓淵繭) = 夢醖糧夢壓鹹淵鑰窪網 鑰選顧範構鹽餘製鏇繭 (遞範膚糧築艱構鏇繭觸, 憲廠範蓋遞顧醖衊淵糧 ~ 鏇艱艱繭衊廠鹽願觸鹽) 更多 | - | 2011-11-22 | ||
OLM 40+AML (OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5) | 糧憲顧醖蓋艱鬱鏇壓艱(膚顧觸構鏇壓壓壓淵繭) = 醖範獵築簾簾膚艱餘衊 鑰選顧範構鹽餘製鏇繭 (遞範膚糧築艱構鏇繭觸, 膚窪憲齋簾壓築獵繭鏇 ~ 鑰鏇鏇製築遞繭蓋遞衊) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用